Quince Therapeutics, Inc. Share Price & Technical Analysis
QNCX · $1.13 (+9.71%)
Healthcare / Biotechnology
$1.13
+9.71%
Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorde…
Price chart
Seasonality
Jun has 2 positive and 3 negative years (last 5 years shown)
-9% return in Jun, 14% avg return in past 3 year Jun month.
-117% return in 2026, 98% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -95% | -19% | -9% | 30% | -15% | -9% | – | – | – | – | – | – | -117% |
| 25 | -14% | -10% | -11% | -17% | -7% | 56% | 2% | -4% | 0% | 1% | 120% | -7% | 109% |
| 24 | 18% | 5% | -18% | -6% | -20% | -16% | 7% | -8% | 11% | 113% | 26% | -7% | 105% |
| 23 | 53% | -5% | 68% | -5% | -2% | 1% | -19% | 8% | -16% | -10% | -6% | 15% | 81% |
| 22 | -52% | -29% | 41% | -41% | -30% | -16% | -14% | -11% | -23% | -27% | -26% | -15% | -241% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consist of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising kit medical devices, syringe kit, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$21.22M
P/E ratio
—
52W high
$45.50
52W low
$0.79
Volume
3,62,685
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹34,400
Abbott Laboratories Cede…
₹32,740
Eli Lilly And Company Ce…
₹28,720
Unitedhealth Group Inc C…
₹17,140
Elevance Health Inc
₹6,770
Frequently asked questions
- What is Quince Therapeutics, Inc. share price today?
- Quince Therapeutics, Inc. (QNCX) last traded around $1.13 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does QNCX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for QNCX. Download the app for real-time alerts.
- How can I analyze Quince Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.